SEQUOIA Trial Evaluates Zanubrutinib in Patients With CLL

Jennifer Brown, MD, PhD director of the Chronic Lymphocytic Leukemia Center at the Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, discusses the purpose of the SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia (CLL).

The analysis of the trial focuses on patients with CLL, specifically without deletion 17p, due to the fact that more tolerable therapies and treatments which can induce lasting responses are needed for this high-risk patient population.

SEQUOIA, an international, phase 3, open-label, randomized study aims to evaluate zanubrutinib (Brukinsa) and how it compares to bendamustine and rituximab (Rituxan) for treatment in patients with CLL.

Transcription:

0:08 | This SEQUOIA study is a registration trial for zanubrutinib in CLL. And there's a primary analysis focused on patients without 17p deletion comparing single-agent zanubrutinib of single agent continuous therapy to bendamustine/rituximab. There was an RMC with single-agent zanubrutinib for patients with deletion 17p, and what was discussed during ASH talking for the first time is arm D, which is also focused on patients with 17 p deletion, but looking at the combination of zanubrutinib and venetoclax [Venclexta].

0:43 | The goal enrollment is 80 patients, and the study design involves 3 months lead-in with zanubrutinib followed by the addition of venetoclax for 12 to 25 months until disease progression, toxicity, or achievement of undetectable MRD with complete remission.